Capital Advisors Ltd’s ImmunityBio IBRX Stock Holding History

Capital Advisors Ltd’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-6	Closed	–	–	1360
2022 Q4	$0	Sell	6 -68	-92%	-$373	﹤0.01%	1400
2022 Q3	$0	Buy	+74	New	+$337	﹤0.01%	1349

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

SSWM

Sheets Smith Wealth Management Winston-Salem, North Carolina $1B AUM 29.77% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Capital Advisors Ltd's IBRX Position: Q1 2023 in Review

Capital Advisors Ltd sold out of ImmunityBio (IBRX) in Q1 2023, closing a stake of 6 shares.

Capital Advisors Ltd first reported a position in IBRX in Q3 2022 and held it in 2 quarters. The position peaked at $0 in Q4 2022. 146 funds tracked by Wall St. Rank hold IBRX as of Q1 2023.

Capital Advisors Ltd reported no remaining ImmunityBio position as of Q1 2023 after selling out during the quarter.
Capital Advisors Ltd sold 6 ImmunityBio shares in Q1 2023.
Capital Advisors Ltd first reported a position in ImmunityBio in Q3 2022 and held it in 2 quarters.
Capital Advisors Ltd's ImmunityBio position peaked at $0 in Q4 2022.
146 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2023.

Based on Capital Advisors Ltd's 13F filing for Q1 2023, filed 3 May 2023.